No Data
No Data
Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Surges 37% Yet Its Low P/E Is No Reason For Excitement
MicroPort Endovascular MedTech Affiliates Get China Nod for Blood Vessel Repair Devices
shanghai microport endovascular medtech(group)co.,ltd. (688016.SH): obtained medical instruments registration certificate
The shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced on September 23 that its holding subsidiary, Shanghai Hongmai Medical Technology Co., Ltd., has obtained the medical instrument registration certificate for fiber occluder spring coils issued by the National Medical Products Administration. The company's representative, Veryan Medical Ltd.'s product, has obtained the medical instrument registration certificate for the peripheral brackets system, BioMimics 3D Stent System, issued by the National Medical Products Administration. The acquisition of the above-mentioned medical instrument registration certificates further enriches the company's existing product categories and expands the company.
Is Weakness In Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.(688016.SH): has accumulated repurchased 0.71% of shares.
As of August 31, 2024, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.(688016.SH) announced that the company has repurchased a total of 880,390 shares through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 0.71% of the company's total share capital of 123,262,117 shares. The highest repurchase price was 98.13 yuan/share, and the lowest price was 78.69 yuan/share. The total amount paid was RMB 78,902,279.90 (excluding stamp duty, transaction commission, and other transaction fees).
MicroPort: Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.'s net income attributable to shareholders in the first half of the year was CNY 0.404 billion, a year-on-year increase of 44.36%.
Microport (00853) has released unaudited financial data for its subsidiary, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd., for the six months ending June 30, 2024. Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. achieved revenue of RMB 0.787 billion, a year-on-year increase of 26.63%; and net income attributable to shareholders of Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. was RMB 0.404 billion, a year-on-year increase of 44.36%.
No Data
No Data